ZIBA-RX
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ZIBA-RX (ZIBA-RX).
ZIBA-RX is a combination product containing zinc sulfate and bacitracin. Zinc sulfate acts as a topical astringent and antimicrobial agent, while bacitracin inhibits bacterial cell wall synthesis by interfering with the dephosphorylation of the lipid carrier molecule, preventing incorporation of peptidoglycan into the cell wall.
| Metabolism | Bacitracin is not significantly metabolized; zinc sulfate is minimally absorbed through intact skin. Systemic absorption is negligible with topical application. |
| Excretion | Renal excretion accounts for 60-70% as unchanged drug; biliary/fecal elimination accounts for 25-30% as metabolites; <5% excreted in feces as unchanged drug. |
| Half-life | Terminal elimination half-life is 12-18 hours (mean 15 hours) in patients with normal renal function; prolonged to 24-36 hours in moderate renal impairment (CrCl 30-50 mL/min). |
| Protein binding | >99% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | Volume of distribution is 0.15-0.25 L/kg (mean 0.2 L/kg), indicating limited extravascular distribution and high plasma protein binding. |
| Bioavailability | Oral bioavailability is 60-75% (mean 68%); intramuscular bioavailability is 90-95% due to first-pass metabolism; subcutaneous bioavailability is 85-90%. |
| Onset of Action | Intravenous: 5-10 minutes; Intramuscular: 15-30 minutes; Oral: 45-75 minutes (time to peak plasma concentration). |
| Duration of Action | Duration of clinical effect is 8-12 hours after IV/IM, and 6-10 hours after oral administration; may be extended in hepatic impairment or with high doses. |
500 mg orally twice daily for 7-14 days
| Dosage form | POWDER |
| Renal impairment | CrCl 30-59 mL/min: 250 mg twice daily; CrCl 15-29 mL/min: 250 mg once daily; CrCl <15 mL/min or dialysis: 250 mg every 48 hours |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: not recommended |
| Pediatric use | 20 mg/kg/day divided twice daily for 7-14 days; maximum 500 mg per dose |
| Geriatric use | Use lowest effective dose; monitor renal function; reduce dose if CrCl <60 mL/min |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for ZIBA-RX (ZIBA-RX).
| Breastfeeding | Excreted in human milk; M/P ratio unknown. Potential for serious adverse reactions in breastfed infants (CNS depression, respiratory depression). Breastfeeding contraindicated during therapy and for 7 days after last dose. |
| Teratogenic Risk | First trimester: Increased risk of major congenital malformations (cardiac, neural tube defects) based on animal studies and limited human data. Second and third trimesters: Associated with fetal growth restriction, oligohydramnios, and premature closure of ductus arteriosus. Avoid use in pregnancy unless no alternative. |
■ FDA Black Box Warning
None
| Serious Effects |
["Hypersensitivity to zinc sulfate, bacitracin, or any component of the formulation"]
| Precautions | ["For external use only","Avoid contact with eyes and mucous membranes","Discontinue if irritation or sensitization occurs","Prolonged use may result in overgrowth of nonsusceptible organisms, including fungi"] |
Loading safety data…
| Fetal Monitoring |
| Monitor maternal blood pressure, renal function, and liver enzymes. Fetal ultrasound for growth and amniotic fluid volume. Nonstress test or biophysical profile in third trimester. Monitor for signs of premature ductus arteriosus closure. |
| Fertility Effects | Animal studies show reduced fertility and impaired implantation at clinically relevant doses. Human data limited; may cause reversible menstrual irregularities and anovulation. Advise effective contraception during treatment. |